Intensified liver-directed radionuclide therapy shows promise for patients with metastatic neuroendocrine tumors

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic neuroendocrine tumors (NETs) while still effectively delivering treatment throughout the whole body. This hybrid approach safely delivered over three times more radiation directly to liver metastases, resulting in encouraging…

Read original article on Medical Xpress - latest medical and health news stories →

Related news